The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]
Ponni Subbiah, MD, MPH
Advertisement
Articles by Ponni Subbiah, MD, MPH
The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
2
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
3
NeurologyLive® Brain Games: November 2, 2025
4
Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240
5
